The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape of germline mutations in hepatobiliary carcinoma: Unrealized risk, untapped clinical trial opportunities.
 
Jewel Samadder
No Relationships to Disclose
 
Margaret Rupp
No Relationships to Disclose
 
Shan Yang
Employment - Invitae
Stock and Other Ownership Interests - Invitae
Travel, Accommodations, Expenses - Invitae
 
Scott T. Michalski
Employment - Invitae
Stock and Other Ownership Interests - Invitae
Travel, Accommodations, Expenses - Invitae
 
Stephen E Lincoln
Employment - Invitae
Stock and Other Ownership Interests - Illumina
 
Robert L. Nussbaum
Employment - Invitae
Leadership - Invitae
Stock and Other Ownership Interests - Invitae
Honoraria - Third Rock Ventures
Consulting or Advisory Role - Genome Medical; Pfizer
Patents, Royalties, Other Intellectual Property - I receive roylaties from NIH and the University of California for a mouse model I created
Travel, Accommodations, Expenses - Pfizer
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TD2
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Edward D. Esplin
Employment - Invitae
Stock and Other Ownership Interests - Invitae